Endoscopic ultrasound-guided choledochoduodenostomy without fistula dilation using a stent with a 5.9-Fr delivery system: Comparison to a conventional procedure with fistula dilation

Takehiko Koga1 | Susumu Hijioka1 | Yosikuni Nagashio1 | Akihiro Ohba1 | Yuta Maruki1 | Motohiro Yoshinari1 | Yuya Hisada1 | Shota Harai1 | Hidetoshi Kitamura1 | Kosuke Maehara1 | Yumi Murashima1 | Yuki Kawasaki1 | Shun Kawahara1 | Kotaro Takeshita1 | Natsumi Yamada1 | Tomoyuki Satake1 | Shunsuke Kondo1 | Chigusa Morizane1 | Hideki Ueno1 | Takuji Okusaka1 | Yutaka Saito2

Abstract

Objectives: To evaluate the feasibility and safety of endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) without fistula dilation using a novel self-expandable metal stent (SEMS).

Methods: This retrospective study examined patients who underwent EUS-CDS for malignant distal biliary obstruction between October 2017 and May 2021 at the National Cancer Center, Japan. The primary outcome was a technical success without fistula dilation. Secondary outcomes were the overall technical success, clinical success, adverse events (AEs), procedure time, recurrent biliary obstruction (RBO), and time to RBO (TRBO).

Results: Forty-one patients were enrolled; 31 patients underwent EUS-CDS without fistula dilation using a conventional SEMS with 7.5–8.5-Fr delivery system (conventional SEMS group), and 10 patients underwent EUS-CDS without fistula dilation using the novel SEMS with a 5.9-Fr delivery system (novel SEMS group). In the novel SEMS group, the rate of technical success without fistula dilation was 90%. There were no differences in overall technical success (100% vs. 97%, p = 1.00), clinical success (80% vs. 90%, p = 0.58), and overall AEs (10% vs. 23%, p = 0.65) rates between the novel and conventional SEMS groups. In the novel SEMS group, no early AEs were observed and no bile leakage into the abdominal cavity was observed on the computed tomography scan after the procedure. The median procedure time was significantly shorter in the novel SEMS group (17 min vs. 24 min, p = 0.03). RBO and median TRBO did not differ between the 2 groups.
INTRODUCTION

Endoscopic retrograde cholangiopancreatography (ERCP) is widely performed as a drainage procedure for patients with malignant biliary obstructions. Recently, endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) has also been used as primary drainage for unresectable malignant distal biliary obstructions. The advantages of EUS-CDS are highly technical and clinical success rates and the absence of the risk of pancreatitis. However, the rate of adverse events (AEs) is high. The most common AEs are bile leakage and peritonitis, and these are associated with the fistula dilation process in the EUS-CDS procedure. The conventional stents used for EUS-CDS are partially or fully covered self-expandable metal stents (SEMSs) with a 7.5–8.5-Fr delivery system, that requires fistula dilation. We previously reported a case in which EUS-CDS without fistula dilation was successfully performed using a novel fully covered SEMS with a 5.9-Fr delivery system. Other than this case, there are no other reports on EUS-CDS using this SEMS. Furthermore, the technical feasibility and safety of EUS-CDS without fistula dilation are also unclear. Herein, we present the outcomes of the patients who underwent EUS-CDS without fistula dilation are also unclear. In this study, we examined the outcomes of patients who underwent EUS-CDS using a novel fully covered SEMS with a 5.9-Fr delivery system and compared these outcomes with those of patients who underwent EUS-CDS using a conventional SEMS with fistula dilation.

PATIENTS AND METHODS

This retrospective study examined 41 patients who underwent EUS-CDS for malignant distal biliary obstruction between October 2017 and May 2021 at the National Cancer Center, Japan. EUS-CDS performed before April 2020 used a conventional fully covered SEMS with a 7.5–8.5-Fr delivery system, and that after May 2020 used a novel fully covered SEMS with a 5.9-Fr delivery system. All patients provided informed consent. The study was approved by the Institutional Review Board of the National Cancer Center Hospital, Japan (2018-1-149), and was performed in accordance with the principles of the Declaration of Helsinki.

The conventional SEMS

The stents we used between October 2017 and April 2020 were conventional fully covered SEMSs with 7.5–8.5-Fr delivery systems (X-suit NIR; Olympus Medical Systems, Tokyo, Japan, HANAROSTENT; M.I.Tech, Seoul, Korea, and Niti-S; Taewoong Medical, Seoul, Korea). The choice of the SEMS was per the echoendoscopist’s discretion.

The novel SEMS

The stent we used between May 2020 and May 2021 was a novel type of braided SEMS (HANAROSTENT Benefit; M.I.Tech) (Figure 1). The SEMS was of the fully covered type with an ultra-thin diameter (5.9-Fr) delivery system. Compared with conventional HANAROSTENT with an 8.5-Fr delivery system, which is the same braided fully-covered SEMS, the stent wire and silicone cover was thinner, and the stent cell size was wider. Therefore, the radial force was down by approximately 40% compared to the conventional HANAROSTENT. The shortening rate after deployment was 30%–40%. The SEMS was available in diameters of 6 and 8 mm and lengths of 6, 8, 10, and 12 cm. During EUS-CDS, the SEMS of 8 mm in diameter and 6 cm in length was our first choice, because it was considered to have a low risk of migration and good fitness to the bile duct. However, SEMSs of other sizes were also selected based on each individual patient’s anatomical condition.

Procedural technique

EUS-CDS was performed by one of the two experts (experience of >50 EUS-guided biliary drainages) or 12 trainee echoendoscopists (experience of >200 ERCP and >50 EUS-guided fine-needle aspirations) under expert supervision. An oblique-viewing echoendoscope (GF-UCT240, GF-UC260; Olympus Medical Systems, Tokyo, Japan and EG-580UT; Fujifilm, Tokyo, Japan) or a forward-viewing echoendoscope (TGF-UC260J; Olympus Medical Systems) was used to perform EUS-CDS. The echoendoscope choice was left to the discretion of the echoendoscopist. However, for the cases in which endoscopic ultrasonography screening was performed.
before the procedure, the angle of the needle insertion, the distance from the puncture point to the hilum, and the scope position were estimated, and the echoendoscope that had greater accessibility with regards these factors were selected. A 19-gauge needle for EUS-guided fine-needle aspiration (EZ shot 3 plus; Olympus Medical Systems and Beacon FNA Exchange System; COVIDIEN, Tokyo, Japan) was used to puncture the extrahepatic bile duct. Subsequently, bile was aspirated via the needle until the diameter of the bile duct was reduced to approximately half, and the hilum was verified using cholangiography. Then, a 0.025-inch guidewire (VisiGlide2; Olympus Medical Systems and M-Though; ASAHI INTECC Corp., Tokyo, Japan) was placed in the bile duct. In the patients with the conventional SEMS, the SEMS was inserted after performing fistula dilation using an electrocautery dilator (Cysto-Gastro Set; Endoflex, Voerde, Germany and Fine025; Medico’s Hirata Inc., Osaka, Japan) or a balloon catheter (REN; Kaneka Medical, Osaka, Japan); in the patients with the novel SEMS, the SEMS was directly inserted without a prior fistula dilation process. The SEMS was deployed through the fistula between the extrahepatic bile duct and the duodenal bulb. Finally, the distal end of the SEMS was pushed by the scope and directed toward the anal side to prevent early stent dysfunction (Figure 2). Abdominal computed tomography (CT) was performed immediately after the procedure to confirm the position of the SEMS, presence of fluid collection, or leakage of the contrast medium (i.e., bile leakage) into the abdominal cavity.

**Definition of outcomes**

The primary outcome was a technical success without fistula dilation. The secondary outcomes were: (1) overall technical success, (2) clinical success, (3) AEs, (4) procedure time, (5) recurrent biliary obstruction (RBO), and (6) time to RBO (TRBO). Technical success without fistula dilation was defined as when the novel SEMS was inserted directly without a fistula dilation process and successfully placed. Overall technical success was defined as a successful novel or conventional SEMS placement with or without the fistula dilation process. Procedure time was measured from when the bile duct was punctured to the deployment and positioning of the SEMS. The following definitions were used in accordance with the Tokyo criteria 2014. Clinical
success was defined as a 50% reduction or normalization of total bilirubin level within 14 days after the procedure. AEs were classified as early (occurring within 30 days after the procedure) and late (occurring after 31 days or later). RBO was defined as the occlusion or migration of the SEMS. TRBO was defined as the time between the initial stenting and the occurrence of RBO.

**Statistical analysis**

The primary outcome, technical success without fistula dilation, was examined only in the patients using the novel SEMS. The secondary outcome was examined in all patients and compared between the novel and conventional SEMS groups. Continuous variables were expressed using medians and ranges, while categorical variables were expressed as proportions. Continuous variables were analyzed using the Mann-Whitney U-test. Categorical variables were analyzed using the chi-square test or Fisher’s exact test. The TRBO was estimated using the Kaplan–Meier method and the log-rank test was used to determine statistically significant differences. A p-value of <0.05 was considered statistically significant. All analyses were performed using SPSS version 25.0 (SPSS Inc.; IBM Corp, Armonk, NY, USA).

**RESULTS**

From October 2017 to May 2021, a total of 335 patients with malignant distal biliary obstruction underwent endoscopic biliary drainage. For 34 patients (10%), EUS-CDS as primary drainage was performed. EUS-CDS as rescue drainage was performed in five of 30 patients with ERCP failure. Two patients were converted to EUS-CDS after transpapillary stenting. A total of 41 patients (12%) underwent EUS-CDS. Of these 31 patients underwent EUS-CDS using the conventional SEMS (conventional SEMS group) [before April 2020], and 10 patients underwent EUS-CDS using the novel SEMS (novel SEMS group) [after May 2020] (Figure 3).

**Patients’ characteristics**

Table 1 shows the patients’ characteristics. The median age was 68 years (range, 40–82 years). Pancreatic cancer was the most common cause of biliary obstruction (88%).

All of the 10 patients (100%) in the novel SEMS group and 26 of the 31 patients (84%) in the conventional SEMS group underwent EUS-CDS as primary drainage. One patient each in both groups had previously received radiation therapy for pancreatic head cancer. Overall,
there was no statistically significant difference between the two groups in terms of clinical characteristics.

**Procedural details**

The forward-viewing echoendoscope was used in four of the 10 patients (40%) in the novel SEMS group and in 20 of the 31 patients (65%) in the conventional SEMS group. In the novel SEMS group, the SEMS with 8-mm diameter and 6-cm length was commonly used (80%, \( n = 8 \)). In the conventional SEMS group, X-suit NIR was used in 18 patients (58%), HANAROSTENT in 10 patients (32%), and Niti-S in two patients (6%). The SEMS with 10-mm diameter and 6-cm length was placed in 14 of the 31 patients (45%), and the SEMS with 8-mm diameter and 6-cm length was placed in 13 patients (42%). The EUS findings showed that the median diameter of the punctured bile duct was 11.5 mm in the novel SEMS group and 12.0 mm in the conventional SEMS group. The median length of the puncture route (distance from the scope to the puncture point of the bile duct on the EUS images) was 10.5 mm in the novel SEMS group and 6.0 mm in the conventional SEMS group with a significant difference (\( p = 0.01 \)).

**Outcomes**

Table 3 shows the outcomes of EUS-CDS. In the novel SEMS group, the rate of technical success without fistula dilation was 90% (9/10). In one patient who required fistula dilation, a forward-viewing echoendoscope was used. The diameter of the punctured bile duct was 19.0 mm and the length of the puncture route was 10.0 mm. Consequently, the technical success was achieved after additional fistula dilation using a 7-Fr electrocautery dilator. The overall technical success rate was 100% (10/10) in the novel SEMS group and 97% (30/31) in the conventional SEMS group. The clinical success rate was 80% (8/10) in the novel SEMS group and 90% (28/31) in the conventional SEMS group. The two clinically unsuccessful patients in the novel SEMS group died of multiple organ failure due to the rapid progression of the primary disease. In the novel SEMS group, the overall AE rate was 10% (1/10). One late AE of non-occlusion cholangitis occurred on postoperative day 46, but there

### TABLE 1 Patients' characteristics

|                                      | Novel SEMS with a 5.9-Fr delivery system, \( n = 10 \) | Conventional SEMS with 7.5–8.5-Fr delivery system, \( n = 31 \) | \( p \) |
|--------------------------------------|------------------------------------------------------|---------------------------------------------------------------|--------|
| Median age, years (range)            | 69 (55–78)                                           | 67 (40–82)                                                    | 0.68   |
| Male, no. (%)                        | 5 (50)                                               | 19 (61)                                                       | 0.71   |
| Cause of distal biliary obstruction, no. (%) |                                                     |                                                               | 0.60   |
| Pancreatic cancer                    | 10 (100)                                             | 26 (84)                                                       |        |
| Ampullary cancer                     | 0 (0)                                                | 1 (3)                                                         |        |
| Metastatic pancreatic tumor          | 0 (0)                                                | 3 (10)                                                        |        |
| Metastatic lymph nodes               | 0 (0)                                                | 1 (3)                                                         |        |
| Indications for EUS-CDS, no. (%)     |                                                     |                                                               | 0.26   |
| Primary drainage                     | 10 (100)                                             | 24 (77)                                                       |        |
| Rescue drainage from ERC failure     | 0 (0)                                                | 5 (16)                                                        |        |
| Conversion from transpapillary stenting | 0 (0)                                               | 2 (6)                                                         |        |
| Treatment for the primary tumor, no. (%) |                                                     |                                                               | 0.83   |
| Chemotherapy                         | 7 (70)                                               | 29 (94)                                                       |        |
| Best supportive care                 | 3 (30)                                               | 2 (6)                                                         |        |
| Post-radiation therapy for primary tumor, no. (%) |                                                     |                                                               | 0.43   |
| Abdominal CT findings                |                                                     |                                                               |        |
| Tumor size, median, mm (range)       | 36.0 (20–69)                                         | 30.0 (10–50)                                                  | 0.20   |
| Ascites, no. (%)                     | 3 (30)                                               | 9 (29)                                                        | 1.00   |
| Duodenal invasion, no. (%)           | 6 (60)                                               | 16 (52)                                                       | 0.73   |
| Duodenal stent placement, no. (%)    | 2 (20)                                               | 1 (3)                                                         | 0.14   |

Abbreviations: CT, computed tomography; ERC, endoscopic retrograde cholangiopancreatography; EUS-CDS, endoscopic ultrasound-guided choledochoduodenotomy; SEMS, self-expandable metal stent.
TABLE 2  Details of the endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) procedure

| Scope, no. (%) | Novel SEMS with a 5.9-Fr delivery system, n = 10 | Conventional SEMS with 7.5–8.5-Fr delivery system, n = 31 | p |
|---------------|-------------------------------------------------|-------------------------------------------------|----|
| Oblique-viewing echoendoscope | 6 (60) | 11 (35) | 0.27 |
| Forward-viewing echoendoscope | 4 (40) | 20 (65) | 0.24 |

| Needle, no. (%) | 0.24 |
|----------------|-----|
| 19-gauge EZ shot 3 plus | 9 (90) | 31 (100) |
| 19-gauge Beacon FNA Exchange System | 1 (10) | 0 (0) |

| Guidewire, no. (%) | 0.003 |
|-------------------|------|
| 0.025-inch M-Though | 10 (100) | 15 (48) |
| 0.025-inch VisiGlide2 | 0 (0) | 16 (52) |

| Stent diameter x length, no. (%) | 0.06 |
|---------------------------------|------|
| 6 mm x 6 cm | 1 (10) | 2 (6) |
| 8 mm x 6 cm | 8 (80) | 13 (42) |
| 8 mm x 8 cm | 1 (10) | 1 (3) |
| 10 mm x 6 cm | 0 (0) | 14 (45) |

| EUS findings | 0.26 |
|--------------|------|
| Diameter of the punctured bile duct, median, mm (range) | 11.5 (7–19) | 12.0 (8–28) |
| Length of the puncture route, median, mm (range) | 10.5 (5–14) | 6.0 (3–20) |

| The first endoscopist, no. (%) | 0.04 |
|-------------------------------|------|
| Trainee | 10 (100) | 20 (65) |
| Expert | 0 (0) | 11 (35) |

Abbreviations: EUS, endoscopic ultrasonography; EUS-CDS, endoscopic ultrasound-guided choledochoduodenostomy; SEMS, self-expandable metal stent.

were no cases of early AEs. In the conventional SEMS group, however, early AEs were observed in six (19%) patients, cholecystitis in two, bile peritonitis in one, non-occlusion cholangitis in one, bleeding in one, and portal vein-bile duct fistula in one. Furthermore, abdominal CT after the procedure showed that there was no leakage of the contrast medium into the abdominal cavity in the novel SEMS group, whereas 13 (42%) patients in the conventional SEMS group had leakage, showing a significant difference (p = 0.02). The median procedure time was significantly shorter in the novel SEMS group than in the conventional SEMS group (17.0 min vs. 24.0 min, p = 0.03). Among the novel SEMS group, RBOs were observed in three (30%) patients, distal migration in two (postoperative days 36 and 61), and occlusion in one (day 245). Two patients with migration were treated by placing a new SEMS through the fistula. In the patient with the occlusion, because the technical approach to the fistula was difficult due to progressive duodenal stenosis caused by tumor invasion, EUS-guided hepaticogastrostomy, and duodenal stent placement were performed. There was no significant difference in the median TRBO between the novel and conventional SEMS group (245 days vs. 155 days, p = 0.46) (Figure 4).

DISCUSSION

We retrospectively evaluated patients who underwent EUS-CDS using the novel SEMS with a 5.9-Fr delivery system or conventional SEMS. In the novel SEMS group, the technical success rate without fistula dilation was 90%. No early AEs were noted. Conversely, the early AE rate in the conventional SEMS group was 19%.

In a recent systematic review, the rate of AEs following EUS-CDS was significant (15%–22%), with bile leakage and peritonitis being the most common.11,16 During EUS-CDS using a conventional fully covered SEMS (conventional EUS-CDS), the fistula dilation process and subsequent device exchange, in particular, are technically challenging and can cause bile leakage. Furthermore, the fistula dilation process is associated with the risk of guidewire displacement and technical failure.3,9 In recent years, one-step EUS-CDS using lumen apposing fully covered metal stent (LAMS) had been performed to reduce AEs.17–22 LAMS is a device specifically designed for EUS-guided procedures. It enables target puncture, fistula dilation, and one-step insertion of the stent delivery system. Although EUS-CDS using LAMS is reportedly effective and safe, it remains unclear whether LAMS or conventional
### TABLE 3  Outcomes of endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS)

|                                | Novel SEMS with a 5.9-Fr delivery system, n = 10 | Conventional SEMS with 7.5–8.5-Fr delivery system, n = 31 | p  |
|--------------------------------|--------------------------------------------------|-----------------------------------------------------------|----|
| Technical success without fistula dilation, no. (%) | 9 (90)                                           |                                                           |    |
| Overall technical success, no. (%) | 10 (100)                                         | 30 (97)                                                    | 1.00 |
| Clinical success, no. (%)          | 8 (80)                                           | 28 (90)                                                   | 0.58 |
| Adverse events, no. (%)            | 1 (10)                                           | 7 (23)                                                    | 0.65 |
| Early adverse events, no. (%)      | 0 (0)                                            | 6 (19)                                                    | 0.31 |
| Cholecystitis                      | 0                                                | 2                                                         |    |
| Bile peritonitis                   | 0                                                | 1                                                         |    |
| Non-occlusion cholangitis          | 0                                                | 1                                                         |    |
| Bleeding                           | 0                                                | 1                                                         |    |
| Portal vein-bile duct fistula      | 0                                                | 1                                                         |    |
| Late adverse events, no. (%)       | 1 (10)                                           | 1 (3)                                                     | 0.43 |
| Non-occlusion cholangitis          | 1                                                | 0                                                         |    |
| Bleeding                           | 0                                                | 1                                                         |    |
| Contrast medium leakage into the abdominal cavity | 0 (0)                                           | 13 (42)                                                   | 0.02 |
| Procedure time in minutes, median (range) | 17.0 (11–25)                                    | 24.0 (11–65)                                              | 0.03 |
| RBO, no. (%)                       | 3 (30)                                           | 20 (65)                                                   | 0.07 |
| Migration                          | 2 (20)                                           | 14 (45)                                                   |    |
| Occlusion                          | 1 (10)                                           | 6 (19)                                                    |    |
| TRBO in days, median (95% CI)      | 245 (0–526)                                      | 155 (117–193)                                             | 0.46 |
| Follow-up period in days, median (range) | 52 (5–302)                                      | 120 (6–645)                                               | 0.17 |

Abbreviations: CI, confidence interval; EUS-CDS, endoscopic ultrasound-guided choledochoduodenostomy; RBO, recurrent biliary obstruction; SEMS, self-expandable metal stent; TRBO, time to recurrent biliary obstruction;

**FIGURE 4**  Kaplan–Meier curves with log-rank test for time to recurrent biliary obstruction in the novel and conventional self-expandable metal stent (SEMS) groups
TABLE 4 Outcomes and endoscopic ultrasound (EUS) findings according to the echoendoscope used in the novel self-expandable metal stent (SEMS) group

| Outcomes of EUS-CDS | OV, n = 6 | FV, n = 4 | p     |
|---------------------|----------|----------|-------|
| Technical success, no. (%) | 6 (100)  | 4 (100)  | 1.00  |
| Without fistula dilation | 6 (100)  | 3 (75)   | 0.40  |
| With fistula dilation | 0 (0)    | 1 (25)   |       |
| Early adverse events, no. (%) | 0 (0)    | 0 (0)    | 1.00  |
| Procedure time in minutes, median (range) | 14.5 (12–25) | 22.0 (11–23) | 0.07  |

EUS findings

| EUS findings | OV, oblique-viewing echoendoscope | FV, forward-viewing echoendoscope | p     |
|--------------|-----------------------------------|-----------------------------------|-------|
| Diameter of the punctured bile duct, median, mm (range) | 10.5 (7–15) | 11.5 (9–19) | 0.61  |
| Length of the puncture route, median, mm (range) | 11.5 (9–14) | 7.0 (5–10)  | 0.02  |

Abbreviations: EUS, endoscopic ultrasonography; EUS-CDS, endoscopic ultrasound-guided choledochoduodenostomy; FV, forward-viewing echoendoscope; OV, oblique-viewing echoendoscope; SEMS, self-expandable metal stent.

The length of the puncture route, insertion angle of the devices, the anatomical structure of the bile ducts, and tissue hardness of the bile duct or duodenal wall. Studies with larger sample sizes are required to investigate these factors further.

Distal migration of the novel SEMS was observed in two patients, both of whom were late-onset cases. Theoretically, a non-dilated fistula is considered narrower than a dilated one. In addition, the radial force of the novel SEMS is 40% lower than that of the conventional HANAROSTENT. Therefore, after deploying the novel SEMS, a deep notch was shaped at the fistula, and the risk of early migration was mitigated (Figure 5). In this study, there was no migration of the novel SEMS when pushing the distal end of the SEMS with the scope and facing it toward the anal side immediately after deployment.

The limitations of this study include its retrospective design with a limited number of patients and follow-up periods. Two experts and 12 trainees were involved in this study, and their respective technical differences and echoendoscope choice might have introduced biases in the outcomes. In addition, the period of the procedure was different between the conventional and novel SEMS groups. Therefore, the learning curves of the echoendoscopists or their team, and the transition in the development of devices other than the SEMSs, might have affected the outcomes of the procedures. Hence, we are currently conducting a phase II prospective trial to evaluate the clinical efficacy and safety of the EUS-CDS procedure performed in the novel SEMS group.

In conclusion, EUS-CDS without fistula dilation using the novel SEMS with a 5.9-Fr delivery system is technically feasible and capable of achieving straightforward, quick, and safe procedures while effectively preventing bile leakage. Although further clinical studies are needed to validate our findings, EUS-CDS without fistula dilation has the potential to be more widely performed...
and could lead to safer primary drainage for many patients.

ACKNOWLEDGMENT
This research was supported in part by the National Cancer Center Research and Development Fund (31-A-13).

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

FUNDING INFORMATION
National Cancer Center Research and Development Fund (31-A-13).

ORCID
Takehiko Koga ©
https://orcid.org/0000-0002-9929-7232

REFERENCES
1. Hara K, Yamao K, Niwa Y, et al. Prospective clinical study of EUS-guided choledochochoduodenostomy for malignant lower biliary tract obstruction. Am J Gastroenterol 2011; 106: 1239–45.
2. Hara K, Yamao K, Hijioka S, et al. Prospective clinical study of endoscopic ultrasound-guided choledochochoduodenostomy with direct metallic stent placement using a forward-viewing echoendoscope. Endoscopy 2013; 45: 392–6.
3. Bang JY, Navaneethan U, Hasan M, Hawes R, Varadarajulu S. Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: A randomized trial (with videos). Gastrointest Endosc 2018; 88: 9–17.
4. Paik WH, Lee TH, Park DH, et al. EUS-guided biliary drainage versus ERCP for the primary palliation of malignant biliary obstruction: A multicenter randomized clinical trial. Am J Gastroenterol 2018; 113: 987–97.
5. Park JK, Woo YS, Noh DH, et al. Efficacy of EUS-guided and ERCP-guided biliary drainage for malignant biliary obstruction: Prospective randomized controlled study. Gastrointest Endosc 2018; 88: 277–82.
6. Nakai Y, Isayama H, Kawakami H, et al. Prospective multicenter study of primary EUS-guided choledochochoduodenostomy using a covered metal stent. Endosc Ultrasound 2019; 8: 111–7.
7. Kawakubo K, Kawakami H, Kuwatani M, et al. Endoscopic ultrasound-guided choledochochoduodenostomy vs. transpapillary stenting for distal biliary obstruction. Endoscopy 2016; 48: 164–9.
8. Kuraoka N, Hara K, Okuno N, et al. Outcomes of EUS-guided choledochochoduodenostomy as primary drainage for distal biliary obstruction with covered self-expandable metallic stents. Endosc Int Open 2020; 8: E861–8.
9. Vila JJ, Páez-Miranda M, Vazquez-Sequeiros E, et al. Initial experience with EUS-guided cholangiopancreatography for biliary and pancreatic duct drainage: A Spanish national survey. Gastrointest Endosc 2012; 76: 1133–41.
10. Ivashita T, Doi S, Yasuda I. Endoscopic ultrasound-guided biliary drainage: A review. Clin J Gastroenterol 2014; 7: 94–102.
11. Wang K, Zhu J, Xing L, Wang Y, Jin Z, Li Z. Assessment of efficacy and safety of EUS-guided biliary drainage: A systematic review. Gastrointest Endosc 2016; 83: 1218–27.
12. Ogura T, Itoi T. Technical tips and recent development of endoscopic ultrasound-guided choledochochoduodenostomy. DEN Open 2021; 1:e8. DOI:10.1002/deo2.8
13. Koga T, Hijioka S, Hisada Y, et al. Endoscopic ultrasound-guided choledochochoduodenostomy without fistula dilation using a novel fully covered metallic stent with a 5.9-Fr ultra-thin delivery system. Endoscopy 2021; 53: E223–5.
14. Matsumoto S, Hara K, Mizuno N, et al. Risk factor analysis for adverse events and stent dysfunction of endoscopic ultrasound-guided choledochochoduodenostomy. Dig Endosc 2020; 32: 957–66.
15. Isayama H, Hamada T, Yasuda I, et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 2015; 27: 259–64.
16. Kakked G, Salameh H, Cheeseman AR, Kumta NA, Nagula S, DiMaio CJ. Primary EUS-guided biliary drainage versus ERCP drainage for the management of malignant biliary obstruction: A systematic review and meta-analysis. Endosc Ultrasound 2020; 9: 298–307.
17. Kunda R, Pérez-Miranda M, Will U, et al. EUS-guided choledochochoduodenostomy for malignant distal biliary obstruction using a fully covered metal stent after failed ERCP. Surg Endosc 2016; 3: 5002–8.
18. Tsuchiya T, Tech AYB, Itoi T, et al. Long-term outcomes of EUS-guided choledochochoduodenostomy using a lumen-apposing metal stent for malignant distal biliary obstruction: A prospective multicenter study. Gastrointest Endosc 2018; 87: 1138–46.
19. Anderloni A, Fugazzola A, Troncone E, et al. Single-stage EUS-guided choledochochoduodenostomy using a lumen-apposing metal stent for malignant distal biliary obstruction. Gastrointest Endosc 2019; 89: 69–76.
20. El Chafic AH, Shah JN, Hamerski C, et al. EUS-guided choledochochoduodenostomy for distal malignant biliary obstruction using electrocautery-enhanced lumen-apposing metal stents: First US, multicenter experience. Dig Dis Sci 2019; 64: 3321–7.
21. Jacques J, Privat J, Pinard F, et al. Endoscopic ultrasound-guided choledochochoduodenostomy with electrocautery-enhanced
lumen-apposing stents: A retrospective analysis. *Endoscopy* 2019; **51**: 540–7.

22. Jacques J, Privat J, Pinard F, et al. EUS-guided choledochoduodenostomy by use of electrocautery-enhanced lumen-apposing metal stents: A French multicenter study after implementation of the technique (with video). *Gastrointest Endosc* 2020; **92**: 134–41.

23. de Benito Sanz M, Nájera-Muñoz R, de la Serna-Higuera C, et al. Lumen apposing metal stents versus tubular self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy in malignant biliary obstruction. *Surg Endosc.* Published online 30 Nov 2020; DOI: 10.1007/s00464-020-08179-y

24. Amato A, Sinagra E, Celsa C, et al. Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis. *Endoscopy* 2021; **53**: 1037–47.

25. Park DH, Lee TH, Paik WH, et al. Feasibility and safety of a novel dedicated device for one-step EUS-guided biliary drainage: A randomized trial. *J Gastroenterol Hepatol* 2015; **30**: 1461–6.

26. Itonaga M, Kitano M, Hatamaru K, et al. Endoscopic ultrasound-guided choledochoduodenostomy using a thin stent delivery system in patients with unresectable malignant distal biliary obstruction: A prospective multicenter study. *Dig Endosc* 2019; **31**: 291–8.